Longevity biotech screening drugs to extend healthy lifespan in pets and people.
| Date | Round | Amount |
|---|---|---|
| Aug 2023 | Funding round Swiss longevity startup Epiterna exited stealth with EUR10M from Daniel Ek's Prima Materia. | $10.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.